Bioinformatics will be one of the keys to success for companies applying genomic tools to drug discovery and development. Demand for greater flexibility, better integration, and higher-value analytical tools is increasing. As a result, a growing number of companies are competing in this field, with a wider range of offerings and business models. During this, the "functional" and "high-throughput" phase of genomics, having top-level software products is simply not enough. The most promising contenders offer not just excellent applications but also access to databases and/or consulting services. This report describes the current and emerging roles of bioinformatics in genomics-based drug discovery and development, the leading tools and those under development, and the strategies that companies are pursuing to meet future demands. More than 60 companies and their technologies are discussed, and 46 are profiled in depth. Proprietary data from Cambridge Healthtech Institute's Drug Discovery and Development Deals Database are referenced for analysis of dealmaking trends. The report also includes commentary, opinion, and strategic insight from our Editorial Advisory Board, comprising leading experts in this field.
Editorial Advisory Board
Andrea Califano, First Genetic Trust; Reinhard Fuchs, Biogen; Steve Gardner, Viaken; Richard Judson, Genaissance Pharmaceuticals; Hwa A. Lim, D'Trends; Tim Littlejohn, eBioinformatics; Andrew Lyall, Oxford GlycoSciences; Eli Mintz, Compugen; Reinhard Schneider, LION Bioscience; and Frank White, InforMax
View Cart
